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Abstract
Triple-negative breast cancer (TNBC) is the most complex and aggressive type of breast cancer encountered world
widely in women. Absence of hormonal receptors on breast cancer cells necessitates the chemotherapy as the only
treatment regime. High propensity to metastasize and relapse in addition to poor prognosis and survival motivated
the oncologist, nano-medical scientist to develop novel and efficient nanotherapies to solve such a big TNBC
challenge. Recently, the focus for enhanced availability, targeted cellular uptake with minimal toxicity is achieved by
nano-carriers. These smart nano-carriers carrying all the necessary arsenals (drugs, tracking probe, and ligand)
designed in such a way that specifically targets the TNBC cells at site. Articulating the targeted delivery system with
multifunctional molecules for high specificity, tracking, diagnosis, and treatment emerged as theranostic approach.
In this review, in addition to classical treatment modalities, recent advances in nanotheranostics for early and
effective diagnostic and treatment is discussed. This review highlighted the recently FDA approved immunotherapy
and all the ongoing clinical trials for TNBC, in addition to nanoparticle assisted immunotherapy. Futuristic but
realistic advancements in artificial intelligence (AI) and machine learning not only improve early diagnosis but also
assist clinicians for their workup in TNBC. The novel concept of Nanoparticles induced endothelial leakiness
(NanoEL) as a way of tumor invasion is also discussed in addition to classical EPR effect. This review intends to
provide basic insight and understanding of the novel nano-therapeutic modalities in TNBC diagnosis and treatment
and to sensitize the readers for continue designing the novel nanomedicine. This is the first time that designing
nanoparticles with stoichiometric definable number of antibodies per nanoparticle now represents the next level of
precision by design in nanomedicine.
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Background
Breast cancer (BC) is the most common malignancy with
266,120 new cases and leading cause of cancer-related mor-
tality (40,920 BC deaths) among women worldwide [1, 2].
Microarray-based expression profiling revealed the exist-
ence of five intrinsic subgroups of BC [3]. Triple-negative
breast cancer (TNBC) owes 15-20% of all the invasive sub-
types of breast cancer [4] and characterized by absence of
expression of estrogen receptors (ER), progesterone recep-
tors (PR) and human epidermal growth factor receptor 2
(HER-2) on tumors cell membrane. Based on the biological
network-driven approach, Bonsang-Kitzis et al identified six
TNBC subgroups whereas Burstein at al identified four
stable TNBC subgroups based on mRNA expression and
DNA genomic profiling [5, 6]. Lack of hormone receptors
(ER/PR/HER-2) in TNBC eliminates the benefits of endo-
crine therapy and treatment, therefore mainly relies on
chemotherapy [7]. Even systemic chemotherapy with clinic-
ally approved drugs reflects poor response, high toxicity
and develops multidrug resistance. In addition, molecular
heterogeneity, high risk to metastasize preferentially to the
viscera, high relapse rate and BRCA mutations (BRCA*)
contribute to poor prognosis and management [8–10].
For early therapeutic intervention, precise diagnosis is
crucial. So far palpation, mammography, ultrasonography,
ultrasound, magnetic resonance imaging (MRI) and
immuno-histochemistry (IHC) are best TNBC diagnostics
in the clinical setup. However, inaccurate diagnosis using
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non-specific contrast agents, false positive findings and
examiner experience are the limiting and decisive factors
to validate TNBC diagnosis. In addition, therapeutic inter-
ventions are limited to surgery, radiotherapy in addition
to cytotoxic chemotherapy with taxanes and anthracy-
clines [11]. These limitations obviate the need to improve
the currently available diagnostic and therapeutic in
addition to explore the novel methods and approaches.
Last two decades of nano-technological advancements
exploring biomedical science for cancer therapy with
contrast agents and drug delivery carriers, now heading
towards more precise and targeted co-delivery of both
diagnostic and therapeutic agents. The availability of
wide variety of nano-carriers were made from polymers,
lipids, nucleic acid, proteins, carbon and metals includ-
ing micelles, dendrimers, liposomes, nanoparticles/tubes,
and DNA tetrahedral /pyramids [12–16]. These smart
nanoparticles encapsulating anti-tumor drugs (arsenal),
and surface coated with specific ligand (key) that eventu-
ally bind with the receptor (lock) expressing on the BC
site (target) and destroy the cells in addition to molecu-
lar imaging (tracer agents) allowing us to simultaneously
diagnose and treat the cancer i.e. Thenanostic approach
for improving current cancer diagnosis and treatment
regime. In recent years, theranostic approach has be-
come more evident to develop efficient drug delivery
system which will be able to cross the biological barriers
for the delivery of right amount of drug at designated lo-
cation and at/for appropriate time finally reduces side ef-
fects and improves therapeutic efficiency [17]. Although
there is no FDA approved theranostic for TNBC, current
approaches in conjugation with novel therapeutic mod-
ules are still indispensable need in clinical setup. As the
therapeutic options for TNBC are limited, implementa-
tion of cancer immunotherapy has been successful in
treating many malignancies. Recently, FDA granted ap-
proval to atezolizumab as first immunotherapy for
TNBC treatment. So, it is worth exploring immunother-
apies and performing clinical studies for treating TNBC
patients with immunotherapy [18, 19].
Triple-negative breast cancer: Current conventional
diagnosis and therapeutics
In clinical setup, radiological, clinical, and pathological
examinations are the main diagnostic approaches for BC
diagnosis. Most widely applied radiological examination
is mammography (using x-ray), but lack of abnormal
features in TNBC tumors, resulting to an inaccurate
diagnosis [20]. To overcome the mammography limita-
tions, ultrasonography representing higher sensitivity
(>90%) should be considered [21], but limited accuracy
for benign tumors, restricts the use for TNBC detection.
MRI is the sensitive with high positive predictive values
in TNBC diagnosis, resulting in false positive findings
which eventually lead to avoidable painful biopsies [22].
Accuracy of TNBC detection by above radiological ex-
aminations requires expertise and experience with clini-
cians to ever evolving radio-graphical technologies and
new cancer/tumor modalities like benign or early stage
cancer. So, the role of immunohistochemistry (IHC) and
onco-pathologist/clinicians is crucial in the clinical iden-
tification of TNBC. The immunohistochemical identifi-
cation of TNBC relies on the hallmark property of
absence/lack of hormonal receptors (ER, PR) and HER-2
in patient’s biopsy tissues [23] and evaluated as best
TNBC diagnosis.
After the proper TNBC diagnosis and considering
other factors like metastatic nature, drug sensitivity/re-
sistance, recurrence and poor prognosis, therapeutic
intervention is done. Breast conservation treatment
(BCT) is the first choice and attempt to avoid mastec-
tomy in TNBC. However, the high incidence of tumor
recurrence even after undergoing radiation treatment
(RT), insist the patient for mastectomy in addition to
radiotherapy [24]. Hormonal therapy which is successful
in other subtype of breast cancer is not applicable to
TNBC due to lack of HER2 and hormonal ER and PR re-
ceptors, thereby necessitates the chemotherapy, which is
currently the mainstay of systemic treatment [25]. Che-
motherapeutic drugs like anthracyclins and taxanes are
commonly used for breast cancer treatment showing
promising response in TNBC [26], but inherited cyto-
toxic effects and current non-targeted strategy of drug
administration need to be resolved with novel technolo-
gies. Repeated chemo cycles with high doses of cytotoxic
drugs destroy cancer cells in addition to the healthy cells
in the vicinity. To avoid the non-specific targeting and
chemo side-effect, nanotechnology based drug delivery
systems are a promising tool. Recent advancements in
nanotechnology and articulation of diagnostics with
therapeutics in theranostic approach as a co-delivery sys-
tem, not only the target the cancer selectively but also
eliminate the cytotoxicity of drugs to other organ.
Nanotechnology-advancements for TNBC: Targeted
Theranostics
In nano-science, developing a promising nanoparticle
entails numerous physiochemical, biological and func-
tional properties for biomedicine application. The most
important is the size; the desired size of nanoparticles
(1-200 nm) and conformation decide the trajectory dy-
namics of the particles which is decisive for nanomedi-
cine formulation. In addition, surface charge and
encapsulation capacity of the nanoparticle are the key
factors for the precise targeted drug delivery using spe-
cific conjugated ligand against the target receptor on
cancer cell. Other properties like high drug loading effi-
ciency, long half-life in circulation with minimum
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systemic toxicity, selective localization, high adhesion at
the tumor environment, enhanced internalization into
the tumor via endocytosis, sustained and controlled re-
lease of imaging agents and cytotoxic drug over right
duration and time in addition to safe bio-elimination
from the body are significant for nanoparticles to be as
theranostics in cancer diagnosis and treatment [27]. Ma-
jority of the above nano-delivery systems rely on the en-
hanced permeation and retention (EPR) effect for
targeted drug delivery. Technical feasibility (high recov-
ery with controlled drug loading and releasing) and fi-
nancial stability for the large-scale production, also
determine the success and research on cancer nano-
medicine. However, application of nano-medicine is lim-
ited in TNBC due to lack of known highly expressed
tumor target and ligands.
Liposomal nanoparticles: A versatile spherical nanocarrier
Liposomes are spherical vesicles (400 nm) molecule with
central aqueous core surrounded by lipid bilayers (Table 1).
The feasibility to encapsulate drug either in lipid membrane
or inside the aqueous core, mark the liposomes the most
versatile nanocarriers with better drug distribution. Gener-
ally, liposomal nanoparticles are designed by the different
methods i.e. extrusion (process of producing nanoparticles
of fixed cross-sectional area), solvent injection (method of
lipid precipitation from a dissolved lipid in solution) and
reverse phase evaporation. Dai et al,[28] targeted the over-
expressing integrin-α3 in TNBC models with cyclic octapep-
tide LXY (Cys-Asp-Gly-Phe (3,5-DiF)-Gly-Hyp-Asn-Cys)
attached liposomes carrying dual drug i.e. doxorubicin and
rapamycin (Table 1). This dual drug targeted approach re-
sulted in improved efficacy as compared to free drug. Simi-
larly, enhanced antitumor activity in TNBC xenograft mice
model has shown with doxorubicin and sorafenib loaded li-
posomes [29]. However, currently marketed doxorubicin li-
posomal formulations are associated with cardiotoxicity, a
novel micelle-encapsulated doxorubicin formulation
(NK911) with improved tumour penetration and reduced
in vivo toxicity is in trial [30]. Liposomal drug delivery sys-
tem for co-delivery of antagomir-10b (anti-metastasis) and
PTX (anti-cancer) was developed to delay 4T1 tumour
growth and reduce the lung metastases of breast cancer
[31]. A significant inhibition and reduction of 82% in the
tumor growth was observed with PEG coated PTX nano-
crystals targeting nude mice (MDA-MB-231/luc) and a lung
tumour metastasis model [32]. Much higher i.e. 87% inhib-
ition of breast tumor growth was reported in xenografted
mice (MDA-MB-231 cells) by lipid-conjugated estrogenic
(bioactive; 47.03%) NPs in combination with cisplatin [33].
So far, paclitaxel and irinotecan loaded liposomes known as
EndoTAG-1 and MM-398 reached the way to clinical stud-
ies in TNBC patients [34].
Micelles:A miracle ball in cancer therapy
Micelles are colloidal particles (5-100 nm) with a hydropho-
bic core formed from Van-der Waals bonds and stabilized
by hydrophilic shell [35]. Owing to its amphiphilic nature,
micelle can deliver both water soluble and hydrophobic
drugs for cancer therapy. Taurin et al [36] synthesized a
micellar system using styrene-co-maleic acid (SMA) to de-
liver a hydrophobic curcumin derivative i.e. RL71 for TNBC
treatment and showed higher toxicity to cancer cell due to
endocytosis mediated higher cellular uptake and slow re-
lease profile (Table 1). Although, above strategy enhanced
the drug uptake but it lacks specificity which is still a ser-
ious challenge in the treatment of metastatic TNBC. Utiliz-
ing the concept of specific ligand-receptor interaction and
the fact that cetuximab (human chimeric monoclonal anti-
body) targets the epidermal growth factor receptor (EGFR)
over-expressed in TNBCs, Kutty and Feng et al [12] devel-
oped cetuximab-conjugated micelles of vitamin E D-alpha-
tocopheryl polyethylene glycol succinate for the targeted
delivery of docetaxel drug (Fig. 1) (Table 1). In-vitro experi-
ments in high EGFR expressing TNBC cell line (MDA MB
468), with different formulation of micelles showed the
IC50 of 0.1715 μg/ml for TPGS micelle with cetuximab, in
comparison to IC50 of 1.12 and 35.26 μg/ml respectively for
TPGS micelle without cetuximab and free drug. These re-
sults have a promising utility in TNBC treatment subjected
to further clinical trials and could be explored as theranos-
tics. A classic example of theranostic and its application in
cancer medicine is given by Muthu et al [37] where they
developed TPGS micelle conjugated with ligand transferrin
which mediated co-delivery of therapeutic docetaxel (drug)
and diagnostic nanoclusterAuNc (imaging) for simultan-
eous detection and treatment in transferrin receptor ex-
pressing MDA-MB-231-Luc breast cancer in vitro model.
Real-time imaging and tumor inhibition were imaged in
xenograft model using above delivery system. Poly (acrylic
acid)-g-PEG i.e. PAA-g-PEG copolymeric micelles carrying
DOX (50 wt/wt %) was developed by Sun et al [31] for the
efficient reduction in lung metastasis and 4T1 mouse breast
tumor growth. However, the only miracle micelle that en-
tered the phase-II clinical trials in TNBC patients is SN-38
(irinotecan) carrying poly(ethylene-glycol)-poly(glutamic-
acid) PEG-PGlu i.e. NK012 micelle [38] and this needs to
be validated in other phases of clinical trials.
Dendrimers: A nanovehicle for siRNA delivery
Dendrimers are synthetic macromolecules (10 nm to 100
nm) prepared by either divergent or convergent synthesis
of branched monomer. Like liposomes, it presents a
cavity-enriched spherical shape with a hydrophobic core
and hydrophilic periphery, making them a unique vehicle
for siRNA delivery [13, 39]. Wang et al.,[40] demonstrated
reduction in tumor vascularization in TNBC xenograft
mouse model using antisense oligo (AODNs) conjugated
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Table 1 Targeted and drug delivery system: Liposomes, Micelles, Dendrimers, Polymeric NP and DNA nanostructure are the few
delivery systems used to carry different therapeutic drugs like paclitaxel, doxorubicin and docetaxel in addition to tracking dye Cy3
as in DNA nanostructure for the precise and targeted delivery using the target specific ligand cetuximab
Thakur and Kutty Journal of Experimental & Clinical Cancer Research          (2019) 38:430 Page 4 of 22
poly(amidoamine) dendrimers. This targeted therapeutic
approach utilizes the higher expression of vascular endo-
thelial growth factor (VEGF) as receptors of AODNs
(Table 1). In another targeted therapy, utilizing siRNA
conjugated poly(amidoamine) dendrimer, Finlay et al.,
[41] have shown the down-regulation of a promising
TNBC target i.e. TWISTItranscriptor factor. Dendrimer
was also assessed as a targeted diagnostic module by
Zhang et al [42] in TNBC tumor mice model. A novel
dendrimer G4PAMAM conjugated with GdDOTA (MRI
contrast) and DL680 (NIR dye) was prepared and injected
subcutaneously in mice as a dual model for imaging and
drug delivery (Table 1). MRI scan and near infra-red
(NIR) fluorescence imaging showing homing of nanoparti-
cles and higher fluorescence signal respectively in the
TNBC tumor, demonstrated targeted diagnostic applica-
tion of this small sized (GdDOTA)42-G4PAMAM-DL680
dendrimeric agent.
Polymeric nanoparticles: A misnomer nanoparticle for
cancer treatment
Polymeric nanoparticle (50 nm-10 μm), if up to 10 mi-
crons in size; can be classified as misnomer nano-
particle. With an additional advantage of encapsulating
drugs and proteins without chemical modification, these
nano-particles can be prepared from natural or synthetic
polymer. Owing to the biocompatibility and reduced
toxicity property, biodegradable polymeric particles viz.
poly(lactic) and copolymer like poly(lactide-co-glycolide)
are being in application for nanoparticle synthesis [43].
Drug molecule could be efficiently encapsulated by the
method of nanoprecipitation, electrospray and emulsifi-
cation; however, Xu et al [44] developed a novel
approach known as PRINT for the synthesis of uniform
sized polymeric nanoparticle. PRINT i.e. particle
replication in nonwetting templates method provide
room for properties customization for effective cancer
therapy. Non-targeted delivery of Pt (IV) mitaplatin drug
using PLGA-PEG i.e. poly-D, L-lactic-co-glycolic-acid –
block-poly-ethylene-glycol nanoparticle, showed higher
degree of tumor inhibition in in-vivo TNBC mice model
(nude mice with MDA MB 468 TNBC cells) [45]. Pas-
sarella et al.,[46] identified a novel peptide (Gle-Ile-Arg-
Leu-Arg-Gly) which specifically recognizes glucose-
regulated protein (GRP78) (Table 1). Using irradiated
TNBC xenograft mice model expressing GRP78 recep-
tor; this group precisely reported apoptosis at the tumor
site by target specific GIALAG-conjugated paclitaxel en-
capsulated polyester nanoparticles. In a recent clinical
trial, 33% response rate was observed in 90% of the pre-
treated metastatic TNBC patients expressing high pro-
tein Trop-2 with IMMU-1322 drug (anti-Trop-2-SN-38
antibody) [47]. Succinobucol with P188 (poloxamer)
combination are emerging as a best oral treatment for
breast cancer. Better bioavailability (13 fold) of succino-
bucol NPs enhances the inhibition of vascular cell adhe-
sion molecule-1 (VCAM-1) invasion and tumor cell
migration [48]. Polymeric NPs are also known to deliver
miRNA and siRNA along with therapeutic drug to reduce
the tumor volume and ultimately tumor growth. PLGA-b-
PEG polymer NPs co-delivered both antisense-miR-21
and antisense-miR-10b with 0.15 mg/kg drug dose
whereas siRNA (multidrug resistance protein) and DOX
co-loaded NP caused overall reduction in tumor growth
and volume (8-fold decrease) respectively [49, 50].
A promising ligand, Arg-Gly-Asp (RGD), either facilitates
targeted delivery of drug or inhibits invasion of cancer dif-
ferently in TNBC tumor models. For instances, cyclic
RGD-functionalized solid lipid NP (RGD-SLN) shown to
inhibit adhesion and invasion of alphavbeta 3 (αvβ-3)
Fig. 1 Diagrammatic representation of the concept of targeted theranostics: a Liposome cavity is loaded with the anti-cancerous drug and the
surface of the liposomal nanoparticle is coated with ligand for the targeted and specific delivery of the drug. In addition to this, tracer helps in
the accurate screening and diagnosis of cancer cells. b Transferrin is conjugated to vitamin-ED-alpha-tocopheryl polyethylene glycol succinate
(TPGS) micelle for targeted co-delivery of therapeutic drug (docetaxel) and diagnostic agent (AuNC) as theranostic.
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integrin receptor over-expressed in invasive TNBC tumors
[51]. This is the perfect example of ligand targeting and in-
ducing inhibition simultaneously in breast cancer cell. Simi-
larly, Zhang et al., [52] synthesized hybrid shealth polymer-
lipid nanoparticles (PLN), conjugated to peptide ligand
RGD and co-loaded with doxorubicin (DOX) and mitomy-
cin C (MMC) i.e RGD-DMPLN. The targeted therapeutic
efficiency of RGD-DMPLN was assessed in metastatic
TNBC mouse model developed using MDA-MB-231-luc-
D3H2LN cell line. Enhanced cytotoxicity in both above
models was achieved by the virtue of DOX-MMC syner-
gism which further enhances by the target RGD-DMPLN.
This type of targeted delivery of synergistic drug enhances
the overall efficacy in cancer treatment and need to explore
more for wider application in breast cancer.
DNA nanostructures in cancer therapy: DNA beyond coding
secrets of life
DNA nanostructures utilize the most fundamental prop-
erty of DNA i.e. Watson-Crick complementary nucleic
acid base pairing to design different nanostructure like
tetrahedral, bipyramids, cages, and cubes with desired
shapes, sizes and configuration. These DNA nanostruc-
tures can incorporate ligands and/or small functional
compounds for site specific attachment and/or for bio-
imaging. Kutty et al., [27] designed a novel self-assembled
DNA nanopyramid, tagged with red-emissive glutathione-
protected gold nanoclusters (GSH-Au NCs) at the base
and actinomycin (AMD) incorporated in the DNA minor
groove. This theranostic DPAu/AMD so far developed for
detection and killing of Escherichia coli and warrant evalu-
ation and modification for other disease/cancer. One of
the major challenges utilizing these structures is to escape
the endosome degradation of DNA nanostructure in
mammalian TNBC. However, same group developed an-
other nanostructure, i.e. DNA tetrahedral (TH) for bio-
sensing and antibody-mediated targeted drug delivery.
DNA tetrahedron self-assembled to form four vertices.
Cetuximab conjugated TH (THC3) with intercalated
doxorubicin (DOX) drug i.e. THDC3 (Table 1) showed
preferential killing of MDA-MB-468 cancer cells, due to
cetuximab which is known to target EGFR over-
expressing cancer cells. Low IC50 value of THDC3 i.e. 0.91
μM in comparison to free DOX i.e. 3.06 μM signifies the
high and specific killing efficiency of THDC3 [16].
Another modified formulation carrying one Cy3 probe
and three cetuximab i.e. Cy3-THC3 shows high sig-
nalling intensity due to increased uptake of Cy3-
THC3 into MDA-MB-68 cells. These two (THDC3
and Cy3-THC3) slight modifications of TH show en-
hanced targeting and killing of cancer cells which
could be an excellent candidate for cancer nano-
medicine especially for TNBC.
Metal nanoparticles: Multifunctional smart hard materials
for cancer therapy
In addition to above discussed nanoparticles, metallic
NPs such as gold (Au), silver (Ag), platinum (Pt), zinc
(ZnO), titanium dioxide (TiO2) and many others are
used in cancer medicine. These nanoparticles may offer
wide opportunity in therapeutic and diagnostic assay
due to their magnetic, optical, thermal and electrical
properties. Surface modification by conjugating different
groups on metal NPs expands the utility for desired clin-
ical outcomes. Different metal NPs utilizes diverse mo-
lecular mechanism like production of intracellular
reactive oxygen species (ROS), increasing oxidative stress
and specific apoptotic tumor cell death [53]. NPs from
the transition class of metals induce hyperthermia (non-
invasive method), to heat up the cells, thereby killing the
tumor cells by converting electromagnetic radiations to
heat. Few metal NPs have inherent potent anti-cancer
activity owing to their unique physiochemical properties.
Gold nanoparticle (AuNPs) is the most extensively in-
vestigated and promising metal NP known to deliver
paclitaxel, a widely known anti-cancer drug. Au NPs de-
signed and synthesised in different shapes and configura-
tions as Au-nanoshells (AuNS), Au-nanorods (AuNR)
and Au-nanocages (AuNC) are now emerging as a versa-
tile nanovehicle for cancer therapy. PEG coated Au NP
in addition to ionizing radiations provided higher sur-
vival rate in mice model of breast cancer [54]. Serum-
coated AuNR have inherited ability to down regulate the
energy generation-related genes expression. Due to re-
duced energy, migration and invasion of cancer cell is
inhibited in both in-vitro and in-vivo. Andey et al.,[33]
also showed the inhibition/suppression of the TNBC
tumor and metastasis using the combination of cisplatin
loaded AuNR and NIR laser. Silver nanoparticles (Ag
NPs) are known for its antiproliferative, proapoptotic,
and anti-angiogenic effects on cancer cells. As a radio-
sensitzing agent, AuNPs reacts with acidic environment
in cancer cells and increases oxidative stress by the pro-
duction of ROS which eventually induce damage and
apoptosis. Liu et al.,[55] observed promising results of
AgNPs treatment followed by radiotherapy on gliomas.
These NPs also observed to inhibit endothelial growth
factor (VEGF) on cancer cells thus limiting the metasta-
sis. Zinc oxide nanoparticles (ZnO NPs) function like
genotoxic drugs for cancer treatment. ZnO NPs form
micronucleus inside the tumor cell, which finally in-
crease mitotic and interphase apoptosis death of the cell
[56]. Asparaginase is a well-known anticancerous en-
zyme used as a chemotherapeutic agent in other cancer
treatment, so ZnO NPs carrying asparaginase, further in-
crease the specificity and stability when given in combin-
ation with paclitaxel and daunorubicin [57]. Even, ZnO
NPs in combination with drugs paclitaxel and cisplatin
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shows reduced toxicity and increase efficacy in breast
cancer cells [58].
Other metal NPs viz. copper (CuO NP), iron-oxide
(Fe2O3), silica, cerium oxide and titanium oxide are also
being explored and used in breast cancer diagnosis and
treatment. Copper oxide NPs (CuO NPs) are described
as green NPs as they were synthesized from Ficus reli-
gioss and Acalypha indica. Metastatic lung tumors of
mouse (B16-F10 cells) are treated using CuO NPs by the
mechanism of apoptosis and ROS generation [59]. Dual
modal therapy employing photodermal and radiotherapy
with Cu-64 labelled copper sulfide NP (CuS NP) showed
the suppression of tumor growth in subcutaneous
BT474 breast cancer model and prolonged the survival
of mice bearing orthotopic 4T1 breast tumors [60]. Hu-
man breast carcinoma cells (in-vitro) and HER2+ breast
carcinoma cells are specifically targeted by anti-HER2
antibody conjugated silica-gold nanoshells in photother-
mal therapy. Cerium oxide NPs (CNPs) function as a
radiosensitizing agent thereby increases the oxidative
stress and apoptotic tumor cell death by following the
biological mechanism of DNA damage [61]. CNPs also
supplement the conventional chemotherapy by deliver-
ing chemotherapeutic drugs like DOX, which provide a
smart approach for cancer therapy. In addition, platinum
and titanium-based NPs are also perceived as a promis-
ing nano-carriers and therapeutic candidate in cancer
photodynamic therapy respectively. An iron-oxide nano-
particle (Fe2O3 NPs) explores the magnetic property for
accurate diagnoses and targeted treatment of cancer as
in squamous cell carcinoma mouse model [62]. A multi-
valent pseudopeptide (N6L) and doxorubicin (DOX)
conjugated to Fe2O3 NPs (MF66) forming a multifunc-
tionalised Fe2O3 NPs known as MF66-N6L-DOX. This
system by combining both hyperthermia and drug deliv-
ery module, presented a better specificity and tumor kill-
ing potential in breast cancer model (athymic nude mice
)[63]. Diagnosis of micrometastasis (0.5 mm dia) and
metastatic breast cancer in transgenic mouse model are
improved by cRGD conjugated Fe2O3 NPs and anti-neu
receptor MAb conjugated superparamagnetic iron oxide
NPs (SPIONs) respectively [64, 65]. Finally, trastuzumab
conjugated modified magnetic polymerosomes named as
herceptin is in clinical trials which can target bone me-
tastasis in a HER2+ breast cancer model (BT474) of
NOD/SCID mice.
Carbon nanotubes (CNTs): Folded grapheme for cancer
therapy
Carbon nanotubes (CNTs) are benzene ring knitted flat
sheets, folded to form single and/or multi-walled cylin-
drical structures. Slight chemical modification imparts
multiple functions with the huge possibility in cancer ther-
apy. Single walled NTs (1 nm-2 nm diameter) having the
ability to penetrate inside cells shows prolonged distribu-
tion and localized effects. Oxidized multi-walled carbon
nanotubes (o-MWNTs) present a novel approach in can-
cer therapy, by reducing macrophages and vessel density
in the tumor [35, 66]. Burke et al., [67] conceptualize the
fact that by hyperthermia, NT promotes cell membrane
permeabilization resulting in tumor mass destruction. So,
he proposed photo-thermal-induced ablation using multi-
walled NT for TNBC therapy. A complex of nanodiamond
and DOX known to inhibit cancer in mouse model by
overcoming drug efflux and increasing apoptosis [68] and
lung metastasis of breast cancer [69].
Ligands for targeted TNBC therapy
Ligands are the small stretch of nucleotides, peptide or
small molecules itself which bind specifically to its re-
ceptor by ligand-receptor interaction. Few of the ligands
were already discussed in the section 3. However other
like aptamers, antibodies, peptides and other small mole-
cules like carbon and quantum dots are also widely
known ligands usedfor targeted or probe based diagnos-
tic in cancer nanomedicine (Fig. 2).
Aptamers: Nucleic acid-based ligands
Aptamers are short oligonucleotides stretches of single-
stranded DNA/RNA. Owing to unique 3D confirmation
of aptamer, it specifically binds the target molecule with
high affinity and strength. The only limitation is the deg-
radation by nucleases; however, its high stability gained
attention for the development of molecular probes. Li
et al.,[70] in their preliminary study, specifically target a
surface membrane protein on TNBC tumor by newly
identified LXL-1 aptamer using cell-SELEX method. Dif-
ferential overexpression of platelet derived growth factor
(PDGF) receptor in TNBC cell line was detected by
Huang et al.,[71] using PDGF-aptamer conjugated to
gold nanoparticles. MCF7 and MDA-MB-415 breast
cancer cells known to over express the mammaglobin
A2 and mammaglobin B1. Hassann et al.,[72] detected
the metastatic breast cancer by MAMA2 and MAMB1
aptamers using highly sensitive terahertz (THz) chemical
microscopy (TCM) using THz radiations. Another 26-
mer G-rich DNA aptamer specifically target the nucleo-
lin receptor in some breast cancer cells [73]. However,
such aptamer based precise targeted diagnosis still need
to be improved and combined with drug delivery for
TNBC theranostic application.
Antibodies: Y shaped key with dual functionality
Antibodies are Y-shaped protein with two epitopes, which
has high selectivity and affinity for its receptor. These are
rated as the best class of targeting ligands. The utility of
antibodies in cancer diagnosis surpasses its high produc-
tion costs. Conceptualizing the differential up-regulated
Thakur and Kutty Journal of Experimental & Clinical Cancer Research          (2019) 38:430 Page 7 of 22
expression of tissue factor (TF) receptor and urokinase
plasminogen activator receptor (uPAR) in TNBC, Shi
et al., [74] suggested and validated the application of the
anti-TF antibody labeled with copper-64 (anti-TF-antibo-
dy-64Cu) using PET imaging in in-vitro TNBC model. Le
Beau et al.,[75] detected NIR fluorophore and Indium-111
(111In) labelled uPAR antibodies using optical and SPECT
imaging respectively. Similarly, anti-EGFR and anti-
VEGFR antibodies conjugated with fluorescent NP and
ultrasound contrast agents are detected using fluorescence
microscopy and ultrasonography. Preclinical study on
TNBC xenograft mice by Rousseau et al., [76] demon-
strates good visualization of TNBC tumor with Iodine-124
(124I) labeled B-B4 antibody (targeting syndecan-1; CD138
antigen) and experience good response (treatment) with I-
131 (131I) radiolabelled B-B4 antibody.
Peptides: Cell penetrating ligands as diagnostic/imaging
sequences
Peptides are low molecular weight ligands with an ability
to target intracellular molecules with high specificity [77].
These target binding peptides sequences can fuse to bac-
terial coat proteins and expressed using genetic engineer-
ing which are finally screened by phage display library
technique [78]. Few peptides for targeting metastatic
breast cancer are RGD, P-selection, tumor metastasis tar-
geting (TMT), and chlorotoxin. Feng et al., [79] observed
binding of CK3 peptide (Cys-Leu-Lys-Ala-asp-Lys-Ala-
Lys-Cys) to NRP-1 trans-membrane protein (neuropilin-
1) by NIR fluorescence imaging in breast cancer of TNBC
mice models. Activable cell-penetrating peptide (ACPPs)
which targets the matrix metalloproteinase (MMP)-2 en-
zymes, when covalently linked to cyclic-RGD peptide,
resulted in enhanced tumor uptake and contrast imaging
in in-vivo TNBC models [80]. Modified Fe2O3 NPs linked
to cyclic RGD peptide resulted in superior and efficient
targeting of αvβ3 integrin receptors [81]. Even the dual
ligand (P-selectin and RGD-peptide) linked liposomal NP
can capture different tumour sites over expressing their
respective receptors on the breast cancer cells [82]. Differ-
ence in pH exploited using pH low insertion peptide
(pHLIP). Ali et al.,[83] designed a pH-responsive MRI
nano-probe i.e. pHLIP-conjugated MRI-NP which specif-
ically internalize and accumulate in in-vitro TNBC cells in
response to its low pH.
Other small molecules
These ligands (<500 Da) are the potential targeting agent
for cancer imaging. The most widely clinically accepted
molecule is 18F-FDG which is a glucose analogue [84]
while other molecule like folate has potential as direct
imaging agents. Meier et al., [85] shows that folate mol-
ecule drives super-paramagnetic iron oxide contrast
agent (P1133) to folate receptors and internalized in the
actively growing TNBC in both in-vitro and in-vivo sys-
tem. Even folic acid conjugated AuNR target the folate
receptor and showed enhanced uptake in 4T1 metastatic
breast cancer cells [86]. Carbon dots (CDots) and
quantum dots (QDs) are useful in biomedical imaging
[87] and holds great promise for early stage TNBC de-
tection. Chemokine receptor type 4 (CXCR4) is a cellu-
lar target involved in the growth and metastasis of
TNBC. Plerixafor or AMD3100 (CXCR4 ligand) conju-
gated poly(lactide-co-glycolide) NPs enhanced siRNA-
mediated gene silencing by improving the cellular uptake
into MDA-MB-231 cells [88]. Similarly, AMD3100
Fig. 2 Diagrammatic representation of ligands and their specific receptors: Folate receptor is targeted by folic acid-conjugated gold nanorod as
nanotherapeutics. Similarly, various other receptors like CD44 and CXCR4 are identified by HA-PTX nanoconjugate and HA-PTX poly(lactide-co-
glycolide) nanoparticle respectively increases the specificity and decrease the adverse effects of the cancer therapy.
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loaded human serum albumin encapsulated NPs targets
CXCR4 on lung metastatic model of breast cancer [89].
Hyaluronic acid (HA) has high affinity to CD44 receptor
therefore an ultra-small (~5 kDa) HA-PTX nanoconju-
gate are taken up via CD44 receptor-mediated endocyto-
sis into metastatic breast cancer (MDA-MB-231Br) cells
[90]. Urokinase plasminogen activator receptor (uPAR)
targeting peptide conjugated to poly (lactic-co-glycolic
acid)-b-PEG polymers carrying two antisense miRNA
showed significantly higher tumor inhibition using [49].
Functionalized fullerenes have been used as novel con-
trast agents in MRI. Other small carbon molecules like
nanocarbons, nanodiamonds with distinctive physical
and chemical properties are also emerging in biomedi-
cine [91, 92] and needs to be extensively studied.
Virus like particles (VLPs) as novel nano-vehicles and
future theranostics
Virus-like particles (VLPs) are self-assembled multimeric
nanostructure (0.1- 100 nm) produced by the expression
of viral structural genes in heterologous systems. The no-
tion of virus-like to VLP is because they are free of any
viral genetic material; and this makes them a versatile
nanovehicle for drug delivery. VLP can be from microbial,
plant or mammalian virus origin and assembled into
spherical and filamentous [93]. Modified VLPs with for-
eign ligands is produced by expressing required heterol-
ogous peptides/proteins/gene sequence on the surface
(capsomers). Also, chemical modification of the functional
groups contained in the structural capsid protein aids tar-
geted mediated therapy. Most remarkable attribute of
VLPs are its small size enough to move in the blood
stream and functional viral proteins on cell surface which
facilitates cell entry/penetration inside the cell. The ability
of VLP to encapsulate small molecules/drug may be ap-
plicable for cancer treatment by targeting and entering the
specific tumor cells by energy-using receptor-mediated
endocytosis and finally, liberating the encapsulated drug
inside the cancer cell. Most astonishing ability is to escape
the endosomes before lysosomal degradation; this favors
the drug availability and protect drug in blood plasma.
The only limitation with the use of VLP as drug delivery
system is that it elicits innate immune response due to
viral proteinaceous particle and readily up taken by den-
dritic cells [94], however on failure of classical chemother-
apy, it gave an optimistic hope for TNBC treatment. Also
increase in drug bioavailability and biocompatibility may
compensate the above disadvantages. Various VLPs are
derived from Human papiloma virus (HPV), Bacterio-
phage, Polyomavirus, Ebola, Influenza, Hepatitis E virus
(HEV) [95] and Tobacco mosaic virus (TMV). Some VLPs
display natural tropism to certain organ or tissues like
HEV VLPs for liver/hepatocytes, however majority of the
VLPs display tropism to sialic acids or heparin sulphates
limits its use as a targeted nanocarrier. A classic example
of VLPs as targeted therapeutic carrier is self-assembled
Bacteriphage MS2 VLP, which is modified with SP94
peptide and encapsulated with doxorubicin/cisplatin/ and
5-fluoro-uracil to selectively deliver and kill human hepa-
tocellular carcinoma (HCC) in Hep3B cell line [96]. Rota-
virus shows natural tropism towards the gut. These
concepts utilize by Cortes et al.,[97] to develop rotavirus
VLP which successfully enter (in-vivo) and deliver green
fluorescent protein (GFP) in intestinal cells of healthy
mice. Adenovirus (Ad3) derived VLP, dodecahedron
chemically conjugated with anticancer antibiotic Bleo-
mycin (BLM), Db-BLM induce death of transformed cells
by causing ds-DNA breaks with lower concentration [98].
So, the popularity of VLPs is attributed by its versatil-
ity, cell-specific targeting, and efficient cell entry, lack of
endosomal sequestering, multivalency, biocompatibility,
large encapsulation and safe delivery system. Despite so
many advantages, VLPs as drug delivery system are in
their infancy and need to be validated on animal model.
Need of nanomedicine for breast cancer therapy: Shift
from conventional to nanomedicine
Conventional chemotherapeutic agents unfortunately asso-
ciated with many limitations. Non-specific target resulting
in systemic toxic effects, adverse clinical outcomes, toxic to
rapidly dividing normal cells leading to chronic toxicity in-
cluding very common manifestation like alopecia, mucositis
and thrombocytopenia. Poor solubility and low bioavailabil-
ity in addition to drug resistance due to possible mechan-
ism involving overexpression of P-glycoprotein and
mutated topoisomerase II further restricts the usefulness of
anticancer agent. Even the tumor/cancer cells structural
makeup limits the clinical outcomes due to poor penetra-
tion of drug because of physical barriers, intercellular junc-
tions controlling drug permeation, and extracellular matrix
proteins [99]. Current problem in cancer therapy is the
rapid drug clearance and limited targeting, which necessi-
tates the emergence of nanomedicine in treating cancer.
Breast cancer primarily metastasizes to the regional lymph
nodes, bone and lungs; however, metastatic breast cancer
has spread to distant sites. Aggressive proliferation, hetero-
geneity and resistance of tumor to therapeutics are few
challenges in treatment of metastatic breast cancer. Adju-
vant therapy including chemotherapy (paclitaxel, eribulin),
hormone therapy (letrozole, tamoxifen) has various long-
term side effects affecting the patient’s quality of life [100].
So far, no targeted therapy in clinic for treating triple nega-
tive, resistant and recurrent breast cancer. Moreover,
TNBC lacks ER, PR and Her-2 /neu and are also difficult to
treat, therefore most likely to recur and disseminate. With
characteristic short overall survival and increase risk of me-
tastasis, its treatment remains a challenge. So, chemother-
apy remains the only option for TNBC treatment with
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anthracyclin and taxane based chemotherapy and neoadju-
nant chemotherapy option [6, 101]. Despite comprehensive
and aggressive management, 50% reoccurrence with 37%
mortality necessitate the advanced, novel and effective ther-
apy [102]. Therefore, multifunctional smart nanoparticles
conjugated with targeting, therapeutic, fluorophore can
cross different biological barriers, target and penetrating
cancer cells by passive method known as enhanced perme-
ability and retention (EPR) effect, and finally release drug in
the cancer cells in a controlled manner.
Novel breast cancer drugs in useor in clinical trials
For the treatment of TNBC, many potential agents are
under different stages of research and development. These
potential agents/inhibitors have different specific targets and
execute its anti-tumor activity differently [103]. A brief sum-
mary on different classes of inhibitors like poly (ADP-ribose)
polymerase (PARP), tyrosine kinase (TK), EGFR, PI3K,
angiogenesis, insulin-like growth factor (IGF), heat shock
protein (Hsp90) and histone deacetylase (HDAC), mamma-
lian target of rapamycin (mTOR), and the mechanism of
their action shown in Fig. 3. Briefly, Poly (ADP-ribose) poly-
merase inhibitors (PARPI) target ssDNA break repairing en-
zyme causing synthetic lethality [104]. Various PARPIs like
olaparib, veliparib, talazoparib have been evaluated in clin-
ical trials on TNBC patients. Olaparib for BRCA-mTNBC is
undergoing phase III (OLYMPIAD; NCT02032823) trial will
likely to be completed in March 2020. Olaparib in combin-
ation with paclitaxel, cisplatin induced overall response rate
of 88% [105]. Receptor tyrosine kinase (RTK) inhibitors tar-
gets in TNBC are EGFR, FGFR, VEGFR and MET. EGFR
expressed in 89% of TNBC and appears a promising thera-
peutic target, but surprisingly majority of the EGFR-TKIs
trials against TNBC are not promising [106]. FGFR as a
therapeutic target in only ~10% TNBC emerged recently,
therefore pan-FGFR inhibitors PD173074 and alofanib in-
hibits the proliferation of SUM52PE and induce apoptosis
by inhibiting MAPK and PI3K signalling cascades [107].
VEGF expression are associated with poor prognosis in
TNBC, however the clinical trials with bevacizumab and
apatinib targeting VEGF2 do not produce promising results
[108]. Contrary to this, sunitinib, anti-VEGFR tyrosine kin-
ase inhibitors are emerging as a potential therapeutic candi-
date in breast cancer trials. MET is a TNBC cell surface
RTK which activates multiple downstream effectors includ-
ing Src, AKT, ERK and RAS. Phase II trial of the tivntinib
(MET inhibitor) is disappointing, however MET+EGFR in-
hibition synergistically reduced cell viability, highlighting the
superior efficacy of this combination [109].
Non-receptor tyrosine kinases (NRTKs) are cytoplas-
mic kinases including PI3-AKT-mTOR signalling cas-
cade, Src, and MEK. Dual mTORC1/2 inhibitors with
everolimus, synergistically reduce proliferation of mul-
tiple TNBC cell lines. However clinical trials on TNBC
Fig. 3 Brief representation of potential inhibitors of various pathways and receptors for the treatment of triple-negative breast cancer. Poly (ADP-
ribose) polymerase (PARP) inhibitors like BSI-20I target ssDNA break repairing enzyme causing synthetic lethality resulting in control of cancer cell
proliferation. Similarly, other class of inhibitors like tyrosine kinase (TK), EGFR, PI3K, angiogenesis, insulin-like growth factor (IGF), heat shock protein
(Hsp90), histone deacetylase (HDAC), andmammalian target of rapamycin (mTOR) employ different mechanism to control and treat TNBC.
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with mTOR+PARP inhibitors and dual mTOR/P13K inhib-
itors are ongoing. PI3-AKT-mTOR pathway represents as
an emerging multi-target of drugs at early stages of clinical
development [110]. MEK is a component of the MAPK sig-
nalling cascade where MEK inhibitors (U0126) significantly
reduce the invasiveness of MDA-MB-2311 in-vitro whilst
lung metastasis is known to be inhibited in xenograft model
by selumetinib [111]. Src is a cytoplasmin oncoprotein and
addition of Src inhibitors i.e. dasatinib to cetuximab + cis-
platin enhanced the inhibition of cell growth and invasion
in TNBC [112]. Epigenetic targets like HDACs and Hsp 90
are also being investigated for TNBC treatment. HDACs
are known to inhibit the expression of DNA repair genes
and tumor suppressor genes. Two clinical trials are investi-
gating HDACi’s combined with DNA methyltransferase in-
hibitors and cisplatin [113]. Hsp90 has the potential to
inhibit multiple growths, signalling and survival cascades.
Phase 1 clinical trials with olaparib and paclitaxel for evalu-
ating Hsp90 inhibitors are ongoing; however, Ganetespib
(Hsp 90 inhibitor) reduced tumor volume in MDA-MB-
231 derived xenografts [114]. Anti-androgens bicalutamide
and enzalutamide, target the androgen receptor (AR) in
various TNBC cell lines which further inhibited prolifera-
tion, invasion and migration of cancer cells suggested them
as a surrogate biomarker for response to other therapies
[115].Voltage-gated sodium channel (VGSC) isneonatal
splice variant of the VGS subtype Nav1. 5. VGSC-
inhibiting drugs such as ranolazine, riluzole and pheny-
toin, all suppress metastatic cell behaviours in vitro and/or
in vivo and are the basis of clinical management of TNBC
[116]. NP based formulations currently in clinical use
for the treatment of metastatic breast cancer are
Liposomes-Doxorubicin nanodrug as Lipo-Dox and
Myocet was approved in 1998 (Taiwan) and 2000
(EMA) respectively for breast cancer [117]. In 2005-
2008, nanoparticle albumin bound to Paclitaxel as
Abraxane and doceaxel (DTX)-polymer NPs (BIND-
014) [118] were approved for advanced metastatic
breast cancer [119]. Similarly, using Paclitaxel as ac-
tive drug, PEG-PLA polymeric micelle formulation as
Genexol-PM was approved by South Korea in 2007
for breast and ovarian cancer. Numerous nanoparti-
cles are being created for cancer treatment, and
many of them are liposomal and polymeric nanopar-
ticle platform. Liposomal nanoparticles with mitoxan-
trone named as plm60-s (Mitoxantrone HCl liposome
injection) are in II phase of clinical trial for breast
cancer [120]. LiPlaCisa liposome nanoparticle with
cisplatin is in II pahse of clinical trial with the prom-
ising results for metastatic breast cancer [121].
Immunotherapeutics: Targeting cancer with immune cells
Immunotherapy is a concept of utilizing intrinsic mech-
anism of host immune system to combat cancer by
enhancing immune system to recognize and kill tumor
cells. This is a novel and revolutionary discovery by 2018
Medicine Nobel Prize winners Professor Tasuku Honjo
(Kyoto University of Japan) and Prof. James P Allison
(University of Texas) for using immune checkpoint
blockade to treat cancer by inhibition of negative im-
mune regulation. Immunotherapy with recent advances
has achieved success and yielded new therapeutics strat-
egy for TNBC treatment [122]. Lack of targets for exist-
ing therapies and immunogenic nature of tumor, render
them good candidate for immunotherapy. Various im-
munotherapies have been tested including immune
checkpoint blockers, cytotoxic T lymphocytes (CTLs) ac-
tivation, adaptive cell transfer-based therapy (ACT) and
modulation of tumor microenvironment (TME). Such
novel immune-modulatory strategies can tackle TNBC
and emerged as personalized immunotherapy (Table 2).
Immunotherapy for triple negative breast cancer
Tumor vaccination comprises of tumor cells or tumor
antigen, to stimulate host to produce effective anti-
tumor immune response. This class of vaccine also
includes DNA vaccines, anti-idiotypic Ab vaccine, anti-
tumor related pathogen vaccine and dendritic cell vac-
cine. Tumor cell vaccines are produced from human
tumor cells that retain its immunogenicity for better
clinical outcome. Belanyenpumatucel-L is an example of
allogenic tumor cell vaccine which specifically target
TGF-beta-2 receptor [123]. Tumor antigen vaccines are
developed by utilizing tumor specific antigen (TSA) and
tumor associated antigen (TAA) [124]. A modified
tumor antigen vaccine containing MHC1 is known as
theratope is in phase III clinical trial. Endocrine therapy
and theratope (Sialyl Tn-KLH; Biomira) combination
showed slowing down of progression in metastatic breast
cancer. DNA vaccine is a bacterium expressed plasmid
with DNA encoding antigenic proteins which can elicit
Ab or CMI response, for example Mammaglobin-A
DNA vaccine in phase-I clinical trial for breast cancer
treatment [125, 126]. Among the anti-idiotypic Ab vac-
cine, Racotumomab is against the surface membrane
glycoprotein of NSCLC (Non-small cell lung carcinoma)
and need to be explored for TNBC.
Apart from tumor vaccine, T-cell based therapy in-
cluding adoptive cell transfer therapy (ACT) is the prime
strategic response against cancer. ACT involves self-
transfer of T cells, lymphokine-activated killer (LAK)
cells, cytokine activated killer (TIL) cells, and macro-
phages activated killer (MAK) cells in patients to kill
tumor cells and improve immune response. Cytokine-
induced killer (CIK) cell infusion therapy with adjuvant
radiotherapy had significantly prolonged disease-free
survival in TNBC patients [127]. Modified approach of
ACT is cascade primed immune cell therapy (CAPRI).
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As an adjuvant therapy, cells obtained from peripheral
blood having tumor immunogenicity, become T cell and
destroy the tumor cells of breast cancer [128]. Chimeric
antigen receptor (CAR) can direct T cells to recognize
antigen expression on tumor cells, however CAR therapy
is associated with cytokine release syndrome (CRS), B
cell aplasia and tumor lysis syndrome (TLS), thereby re-
stricts the utility in cancer treatment [129].
Cytokine therapy treats cancer by multiple ways. The
most common way is by elevating cytokines levels, en-
hancing expression of tumor-related Ag, by stimulating
immune effector cells. IL-2 promotes T cell proliferation
and activation of NK, CTL along with B cell proliferation
[130]. However IFN-γ approved for treatment of renal
cell carcinoma, CK therapy would be an attractive area
in breast cancer treatment.
Therapeutic antibodies targeting CD3, CD19, CD20,
CD22, CD30, CD33, epithelial cell adhesion molecule,
VEGF, EGFR, HER2, NF-κβ, CTLA-4, PD-1 and PD-L1
receptors used as immunotherapeutics. Currently, her-
ceptin and NeuVax vaccine (Immunodominant nanapep-
tide with GM-CSF) are targeted against HER2-expressing
breast cancer. Zoledronate is in clinical phase–II for triple
-negative breast cancer treatment [131]. Antibodies like
cetuximab inhibiting EGFR; bevacizumab targeting VEGF;
rituximab targeting CD20, and ipilimumab, nivolumab
and pembrolizumab immunostimulating anti-CTLA-4,
anti PD-1 and anti-PD-L1 respectively are the promising
antibodies as immunotherapeutics for TNBC treatment.
Immune checkpoints are protective effector molecules
of human immune system. Inhibitors of CTLA-4, pro-
grammed death 1 (PD-1) and programmed death ligand-1
(PD-L1) are immune check point blockers. Clinical trials
with checkpoint inhibitors in breast cancer have only been
recently initiated. CTLA-4/CD152 checkpoints are
expressed on CD8 T cell, CD 4 T cell, Fox P3+ regulatory
and NK cells involved in immune activation [132]. Ipilimu-
mab (humanized IgG1MAb) and tremelimumab (human
IgG2 MAb) are FDA approved antibodies used as CTLA-4
inhibitors in different cancer treatment which reactivate T
cells and eventually enhance anti-tumor immune response.
PD-1 is monomeric glycoprotein/checkpoint receptor,
expressed by T cells surface and binding to PD-1 is blocked
by blocker would enhanced T cell immune response [133].
Nivolumab (humanized IgG4 MAb) and pembrolizumab
(humanized IgG4 isotype MAb) are FDA approved PD-1
targeting antibodies whichinhibit PD-1 and shows thera-
peutic benefit in melanoma and NSCLC in two different
phase III trials (Checkmate-057 and Checkmate -037) [134].
Nivolumab is being evaluated as monotherapy in an adap-
tive phase II trial (NCT022499367) and in combination with
TAK-659 (TK inhibitor) in phase 1b (NCT02834247) of
metastatic TNBC [135]. Pembrolozumab blocks interaction
between PD-1 and PD-L1/PD-L2 and evaluated as mono-
therapy by screening 111 metastatic TNBC patients in phase
1b (KEYNOTE-012; NCT01848834) trial [136]. Other trials
assessing the efficacy and response of pembrolizumab as
monotherapy in metastatic TNBC are phase II
Table 2 Ongoing clinical trials for TNBC: Different class of agents are being tested (eg. Anti-PD1- Pembrolizumab) on different
subjects (eg. metastatic TNBC) and given in combination with other chemotherapeutic agents as the promising immunotherapy for
TNBC treatment. These trials are approved with identifier and are in different phase of their evaluation with their probable
compeltion date
Class of agents Agent Phase Participants Combinatorial agent Completion Identifier
AR antagonist Enzalutamide 2 Stage I-III AR positive TNBC - April 2019 NCT02750358
Anti-PD1 Pembrolizumab 1/2 Recurrent TNBC, mTNBC PLX3397 (TkI of KIR, CSFIR) May 2019 NCT02452424
Anti-PD1 Pembrolizumab 2 mTNBC Carboplatin + gemcitabine June 2019 NCT02755272
Hsp90
inhibitors
Onalespib 1 Metastatic solid tumor, Recurrent
TNBC
Olaparib October 2019 NCT02898207
AR antagonist Enzalutamide 1/2 AR positive mTNBC Taselisib (PI3K inhibitor) December
2019
NCT02457910






PARPi Olaparib 3 TNBC, Germline BRCA1/2 mutation - March 2020 NCT02032823
PARPi Olaparib 1b Recurrent TnBc AZD2014 (mTORC1/2 inhibitor) November
2020
NCT02208375
AR antagonist Enzalutamide 2 AR positive mTNBC Paclitaxel December
2020
NCT02689427
Anti-PD1 Pembrolizumab 2 Advanced TNBC or mTNBC - January 2021 NCT02644369
Anti-PD-L1 MPDL3280A 2 TNBC Nab-paclitaxel February 2021 NCT02530489
Anti-PD1 Pembrolizumab 1/2 mTNBC Paclitaxel May 2021 NCT02734290
Thakur and Kutty Journal of Experimental & Clinical Cancer Research          (2019) 38:430 Page 12 of 22
(KEYNOTE-086; NCT02447003) and phase III (KEY-
NOTE-119; NCT02555657) trials. Combination of pem-
brolizumab and chemotherapy is also evaluated in
randomized phase III (KEYNOTE-355; NCT02819518)
trial for metastatic TNBC. Effect of adjuvant treatment
with pembrolozumab is also evaluated in phase III
(SWOG-S1418, BR006; NCT02954874) trial with 1000
TNBC patients. Higher levels of tumor-infiltrating lym-
phocytes (TILs) have prognostic significance and sug-
gest immune response to tumor associated antigen in
TNBC [137]. PD-L1 expressed on tumor cells exerts in-
hibitory effect on T cell and tumor-infiltrating inflam-
matory cells by interacting with PD-1 receptor on T
cells. Clinically important PD-L1 inhibitors are atezoli-
zumab (IgG1 isotype MAb), avelumab (human IgG1
MAb), and durvalumab (IgG1 MAb). Atezolizumab
binds selectively to PD-L1 on immune cells/tumor cells
and prevent interactions with the PD-1 receptor. A
phase I (NCT01375842) trial with fifty-four metastatic
TNBC patients [106] to assess the safety profile of ate-
zolizumab and phase 1b (NCT01633970) trial in com-
bination with nab-paclitaxel emerged as attractive
chemoimmunotherapy in metastatic TNBC treatment
[138]. Combined efficacy of atezolizumab and chemo-
therapy is evaluated for TNBC in phase III
(NCT02620280) neoadjuvant trial. Recently, FDA
granted approval to first immunotherapy i.e. Atezolizu-
mab (Tecentriq, Genetech/Roche) plus chemotherapy
nab-paclitaxel (Abraxane, Celgen) for the first-line
treatment of unrespectable locally advanced or meta-
static, PD-L1-positivetriple-negative breast cancer
(TNBC) [18]. Atezolizumab plus nanoparticle albumin-
bound (nab)-paclitaxel synergistically enhance the anti-
cancer activity and prolonged the progression-free sur-
vival among patients with metastatic triple-negative
breast cancer in both the intention-to-treat population
and the PD-L1-positive subgroup (Impassion130;
NCT02425891). Velumab is undergoing a phase Ib
(JAVELIN; NCT01772004) trial in a cohort of 168
metastatic breast cancer patients. Another phase III
randomized trial (A-BRAVE; NCT02926196) was con-
ducted in 355 TNBC patients with avelumab to evalu-
ate adjuvant treatment. Durvalumab blocks the
activation of PD-1 receptor expressed on activated T
cells. Various clinical adjuvant therapeutic trials are go-
ing with different stage TNBC patients. Phase Ib
(NCT02826434) trial for stage II/III TNBC patients in-
clude durvalumab with PVX-410 vaccine as adjuvant;
however, another phase I/III (NCT02489448) trial with
neoadjuvant nab-paclitaxel with doxorubicin, cyclo-
phosphamide and durvalumab in stage I/III TNBC pa-
tients. Other targets like lymphocyte activating gene 3
(LAG3) and T cell immunoglobin and mucin-3 (TIM-
3) are expressed on activating T cells, NK and
monocytes and served for immune checkpoint inhib-
ition [139].
Immuno-interventions are being explored as neoadju-
vant therapy against TNBC. Melanoma-associated
antigen-3 (MAGE-3) and alpha-lactalbumin antigen are
expressed in breast and tested as a tumor vaccine to pro-
duce effective anti-tumor immunity. Significant suppres-
sion of breast tumor is reported in mice vaccinated with
GM-CSF adjuvant alpha lactalbumin vaccine [140]. Allo-
genic Dendritic cell (DC) fused TNBC vaccine can
stimulate T cell proliferation and produce tumor specific
immune response against TNBC, possibly by increasing
IL-12 aand IFN-γ levels [141]. Many clinical trials of im-
munotherapy agents are in progress with a hope to
change the standard of TNBC care and treatment.
Nanomaterials assisted immunotherapy for TNBC
Nanotechnology provides efficient and smart nano-
delivery systems facilitating the delivery of immunostimu-
lating adjuvants and tumor antigens to enhance antigen
presentation and immunity which aids in treatment of
metastasis. An improved and clear understanding of
TNBC immunogenicity has led several trials with different
immunotherapeutic agents, with the hope of developing
new immunotherapeutic modalities in TNBC [137, 142].
Approximately, 45 formulations, majority of liposomal
NPs containing GM-CSF, anti-TNF-α are approved for
clinical use in cancer therapy. Nano-particulate carriers
improve solubility and bioavailability of immunotherapeu-
tic and protect them from degradation, therefore enhance
potential efficacy.
Nanoparticles (NPs) assist improvement in antigen ex-
pression pathways by the delivery of epigenetic modula-
tors and immunostimulator cytokines [108]. NPs
mediated transfer of epigenetic inhibitors has been effica-
cious in initial trials of breast cancer. DOX with decitabine
NP (DNMTi) shown to increase the sensitivity of breast
cancer cells [143]. Similarly, vorinostat (HDACi) delivered
with improved solubility (four-fold), half-life and pharma-
cokinetics using the poly-ethylene-oxide-polylactic acid
(PEO-PLA) copolymer micelles [144]. Cytokines like IL-2,
IFN-γ,TNF-α and thymosin are FDA approved immunos-
timulator for cancer treatment (renal cell carcinoma).
These cytokines directly stimulate NK, CTL and immune
effector cells and finally enhance the immune response.
Liposomal NPs mediated delivery of cytokines, for ex-
ample PEG-coated liposomal NPs assisted delivery of IL-2
cytokines has reduced tumor growth [145]. Cytokine ther-
apy in combination with cancer vaccines may able to
stimulate and increase effector T cells, but still more re-
search needs to be done for TNBC nanomedicine.
Tumor micro-environment (TME) is the critical factor
which affects the delivery and efficacy of diagnostic and
therapeutic modules. NP mediated delivery of soluble
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mediators like TGF-β receptor inhibitor broadly in-
creases the number of CD8+ T and NK cells. Other
strategy to knockdown TGF-β by 50% in melanoma
using liposome-protamine-hyaluronic (LPH) acid NP co-
delivered with siRNA (TGF-β) and cancer vaccine [146].
Stimulator of IFN gene (STING) resides inside the cell
and is becoming an exciting target for cancer therapeu-
tics. cGAMP encapsulated liposomal NPs (cGAMP-NP)
penetrates inside the cell for its intracellular delivery.
cGAMP-NP directed activation of STING, activate hu-
man macrophages to increase IFN-γ producing T Cells
which eventually reduce melanoma tumor load [147]. A
self-degradable hyaluronic acid (HA) integrated pH sen-
sitive dextran NP patch which encapsulates PD1 and
glucose oxidase (GOx) was developed as immunothera-
peutic module by Wang et al.,[148]. In melanoma mouse
model (B16F), a strong robust immune response was in-
duced with this novel microneedle patch. CTLs response
in cancer therapy is also induce by lipid-calcium-
phosphate (LCP) NPs mediated transfer of cancer anti-
gen. B16F10 melanoma also treated with lipid NP
formulation containing mRNA for gp100 and TRP2,
thereby inducing strong cytotoxic CD 8 T cell response
resulting in overall shrinkage of tumor in mice [149].
Inherited immunostimulating immunotherapeutic in-
volve metals like selenium (Se) and mica posing inherit
immunostimulating properties. SeNPs exhibit its anti-
cancerous activity by stimulating neutrophils, T and B
lymphocytes and NK cell mediated cytotoxicity [150].
However, the oral and nasal mode of administration is
the major drawback of this therapy and needs re-
evaluation in cancer immunotherapy.
Other nanocarriers facilitating the immunotherapy
are liposomes, exosomes and nanospheres. Cationic li-
posomal NPs with poly (I/C) and peptide emerged as
cancer vaccine formulation showing increased T-cell
response [151]. Fc receptor targeting tumor peptide
vaccine (nano-liposome) with Palm-IL-1/MAP-IFN-γ
peptide as adjuvant, targets the DCs and produce
strong anti-tumor response in cancer patient. Ascetic
cell exosomes (small membrane vesicles) also induce
production of cytotoxic T-lymphocytes when given
with granulocyte-macrophages colony-stimulating fac-
tor (GMC-SF) in phase 1 clinical trials [152]. Com-
bined delivery of siMDR1 (multi-drug resistance gene)
with DOX using hollow carbon nanospheres facilitates
90% reduction of tumor weight in mice by down-
regulating MDR1 protein expression [153]. Even the
antigen-capturing nanoparticles (AC-NPs) induce
CD8+ cytotoxic and CD4+ T cells population, thereby
improving cancer immunotherapy [154].NP carrying
bevacizumab and CRLX101 showed good efficacy in
TNBC treatment [155]. Polymeric NP based vaccine
with IFN-stimulated gene and albumin NPs with
TA99 Mab can turn phagocytes and lifting neutro-
phils against cancer [156, 157].
Autophagy is known to promote or suppress cancer
development (double edge sword), therefore recently ex-
plored as immunotherapeutic modality. Autophagy is a
genetically well controlled defence mechanism which
has been reported to modulate immune system. Sulfo-
raphane (SFN) induce autophagy by down regulating the
expression of histone deactylase (HDAC6) mediated
phosphatase and tensin homolog (PTEN) activation in
MDA-MB-231 and MDA-MB-468 cells which signifi-
cantly sensitizes TNBC to DOX. Autophagy induction
(SFN) in combination with DOX (therapeutic) inhibits
tumor growth and may provide an effective approach for
TNBC therapy [158]. Autophagy mediated suppression
of cancer is promising treatment modality and warrants
detailed investigation.
Nanoparticle infiltration: Route from blood vessels to
breast tumor site
Nanoparticles (NPs) with ligands for targeted drug delivery
or carrying diagnostic and/or therapeutic (theranostics), or
loaded with immunotherapeutic with immunomodulating
or immunostimulating anti-cancer affects needs to be
injected, circulated in blood vessels and finally needs to be
targeted at the cancer site by crossing or travelling the
endothelial barrier. Size, shape, charge and density of nano-
particles are the important parameters which decide the
trajectory, dynamic, stability and distribution while circula-
tion in blood stream and subsequent mechanism of infiltra-
tion in tumor tissues and cells. To reach the tumor site and
to successfully deliver the therapeutic drug, vascular barrier
needs to be crossed.
NPs usually follow two different strategies i.e. passive
route and active route to target cancer site. Majority of
the nanomedicine assumes and follow the passive
phenomenon known as enhanced permeability and re-
tention (EPR) route which is totally dependent on the
tumor type and stage of cancer. In EPR effect, NPs pas-
sively cross leaky vessels of tumor tissues and accumu-
late into the cancer cells. Degree of leakiness depends on
the tumor location, vasculature and progression stage
[159]. Nano-carriers once injected for the systemic deliv-
ery of cancer therapeutics; in the circulation they are
coated with plasma proteins and readily available to
clearance by mononuclear phagocyte system (MPS). NPs
avoid MPS by PEG surface coating and this NP extra-
verted from tumor blood vessels into tumor by margin-
ation (ability to flow towards blood vessels walls) leading
to longer half-life through prolonged circulation in blood
[160]. Inside tumor cell, NPs release their cargo by the
process of particle erosion and diffusion. Non-spherical
particles (100 nm) marginate more rapidly and extravert
through the leaky tumor vasculature and penetrate into
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tumor mass. Surface modification involving zwitterionic
ligands eg. cysteine and glutathione or PEGylation facili-
tate escape of NPs from reticuloendothelial system (RES)
and finally reach the target tumor tissue [161]. Even
poor lymphatic drainage system provides permeability to
cross the barrier and allow NP to passively diffuse/pene-
trate to the target the cancer site. So, EPR effect is
mostly seen in mature tumor and attributed by the
nutrient-starved condition in tumor.
Contrary to above passive route, greater selectivity and
specificity for cancer cells is achieved surface modifica-
tion of NPs with ligands like transferrin, folic acid and
antibodies for specific targeted therapy on glycan surface
of the tumor cells [162]. Transcellular route and move-
ment between the endothelial cells are the newer strat-
egies. Receptor mediated internalization is facilitated by
the endothelial cells (ECs) surface receptors following
transcellular transport across the EC barrier is accom-
panied with certain shortcoming like lysosomal digestion
in EC cellular processing and few EC specific markers.
Therefore, more profound mode is paracellular route
having VE-cadherins and occludins junctions across the
narrow intercellular spaces between two endothelial cells
(EC). This gap between the ECs is the new target and
needs to be widening by NP to access the tumor site. So,
for, targeting early and benign cancer, nanomaterial in-
duced endothelial leakiness (NanoEL) phenomenon is
emerging. NPs are now designed to induce endothelial
leakiness forming capillary beds without EPR effect.
Physiochemical intrinsic properties of NPs like charge
and density regulates the NanoEL and cancer progres-
sion. Gold NPs (10-30 nm) is recently exploited as
NanoEL inducing particles in human mammary endo-
thelial cells [163]. Using charge as an important entity,
AuNPs charge (negatively and positively charged NPs)
could be tuned for NanoEL effect. Negatively charged
gold NPs (-AuNPs) could be attracted and bound to-
wards positively charged cell-cell junction and could in-
duce NP driven leaky effect to access the tumor. Using
the same concept, positively charged AuNPs (+AuNPs)
are attracted by glycocalyx and modulate the degree of
NanoEL effect by endocytosis (paracellular route) into
the endothelial cells (EC) barrier. However, based on
bouncing particle hypothesis negatively charged NP
(-AuNPs) caused more NanoEL effect (Fig. 4, [164]).
Micron sized gaps between endothelial cells could be
easily passed by NPs but not the nanosized gaps between
microvascular capillary. Therefore, size of nanoparticle is
another important feature, as smaller sized NPs can eas-
ily penetrate and accumulate in the leaky tumor vessels.
Even density of the NPs dictates the NanoEL effect.
Using SiNPs library of varying densities, Tay et al, [165]
reported high endothelial permeability with particle
density between 1.57 g/cm3 to 1.72 g/cm3. Same group
of researchers tried various small sized (15-25nm) NPs
like titanium dioxide (TiO2), silica dioxide (SiO2) and sil-
ver (Ag) for NanoEL effect. These NPs randomly entered
nanometer wide gaps of the adherens junctions between
endothelial cells disrupt the VE-Cad-VE-Cad interac-
tions and produce micron sized gaps between endothe-
lial cells. Setyawati et al., [166] also demonstrated a
novel non-receptor mediated endothelial cell leakiness
(ECL) by TiO2 NPs targeting specific interaction with
VE-cadherin protein. TiO2 NPs migrate into the inter-
endothelial adherents junction niche and binds directly
to VE–cadherin resulting in cascade of intracellular reac-
tions and finally disruptcell–cell interactions. This facili-
tates application of the nanomedicine for the treatment
of cancer. Surface re-modelling of the NPs like addition
of chemical groups on the surface of Nanodiamonds also
known to modulate the degree of leakiness in the vascu-
lar barrier. Such modified nanodiamonds widen the
paracellular route opening of EC barrier by increasing
the intracellular Ca2+and ROS, inducing the cytoskeleton
remodelling resulting in vasculature leakiness [167]. This
demonstrated the possibility for doxorubicin to pene-
trate effectively through leaked vascular barrier to reach
the cancer cells with high efficacy of drug delivery.
NanoEL effect although is beneficial in enhancing the
delivery of drug carrying NP, but it’s no specificity to in-
duce spontaneous leakiness in other blood vessels could
have adverse effects. Studies by Setyawati et al.,[163]
also showed side-effects of TiO2-NanoEL induced leaki-
ness of subcutaneous blood vessels in mice and en-
hanced circulating melanoma metastasis to lungs in the
mouse model. These inherited side-effects of NPs in-
duced non-specific NanoEL effect and high probability
of interaction with biological tissues has raised safety
concerns which need to be addressed. Designing of spe-
cific and smart NanoEL driven nanoparticles can be the
future of cancer nanomedicine which could target the
wide spectrum of tumor including TNBC.
Novel research for cancer detection and treatment: In
news
Scientists from University of Queensland developed a
method to detect cancer in 10 min using blood sample
with accuracy of 90%. They developed such sensitive de-
tection test using simple colour changing fluid to reveal
the presence of malignant cells based on the hypothesis
that normal DNA and Cancer DNA shows different ad-
herence to metal surfaces and stick differently [168]. In
addition, researcher from Rosalind Institute developed a
revolutionary high-speed camera that can take 100 mil-
lion photos per sec at 1-megapixel resolution across the
spectrum from Infra-red (IF) to ultra-violet (UV). This
high-speed camera helps the researchers to see how a
drug reacts with a cancer tumor at a microscopic level
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in Real-Time [169]. Recently, Israeli scientists claim to
develop 100% cancer cure by early 2020, using a treat-
ment known as MuTaTo which stands for Multi-Target-
Toxin [170]. This treatment is developed by Accelerated
Evolution Biotechnologies Ltd (AEBi) based on the SoAP
Technology. Successful preliminary trials on mice using
a combination of cancer targeting peptide and MuTaTo
toxin, showing the specificity towards cancer cells and
terminate cancer cells without harming normal healthy
cells and tissues. The concept that makes MuTaTo
treatment different from existing treatments is the
attacking cancer cells receptors from 3 different direc-
tions simultaneously at the same time and reflect the
scope of hyper-personalized treatment to each patient in
the long run. Recently the researchers from the Univer-
sity of Queensland and Albert Einstein College of Medi-
cine jointly developed a statistical approach known as
Oncomix [171] to examine breast cancer data from The
Cancer Genome Atlas patient database and identified
the most promising target known as Chromobox 2
(CBX2) which has been shown to have high levels in ag-
gressive sub-type of breast cancerand therefore could be
a potential breast cancer treatment target. Oncomix,
captures transcriptional heterogeneity in tumor and
identifies oncogene candidates that were over expressed
in a subset of breast tumors. Intronic DNA methylation
was strongly associated with the over expression of
Chromobox 2 (CBX2), an oncogene. CBX2 over expres-
sion in breast tumors was associated with the up regula-
tion of genes involved in cell cycle progression and with
poor 5-year survival [171]. This discovery highlights the
potential value of the Oncomix approach and will open
new therapeutic avenues and move us closer to person-
alized medicine.
Artificial intelligence (AI): Advanced cancer diagnosis and
treatment (Futuristic approach)
Artificial intelligence revolutionizes every bit of science
whether it is engineering, robots, defence, nanotechnol-
ogy or medical science. Everything is now going smart
whether it is our phones or watches, thanks to artificial
intelligence. Recently, Cancer Research UK Imperial
centre, DeepMind Health, AI health research team at
Google and UK funded OPTIMAM mammography
database at the Royal surrey country hospital NHS foun-
dation trust collaborated to improve breast cancer diag-
nosis using AI [172]. Machine learning technology from
DeepMind Health and de-identified mammograms, pos-
sibly train computer algorithm to analyse these images
more accurately, leading to earlier detection and
Fig. 4 Schematic representation of different routes followed by nanoparticles in cancer therapy. (1) In transcellular route, the drug carrying
nanoparticle injected into the bloodstream passes through the endothelial cell and reaches as the cancer site. (2) Whereas in paracellular route,
the nanoparticle passes through the inter-endothelial cell spaces and known as active targeting. These nanoparticles induce leakiness by
widening the gap between the endothelial cells and enhance the cancer cell targeting also known as naoEL effect. (3) Passive targeting is the
classical and common phenomenon where the nanoparticle transverse through the leaky vasculature by EPR effect to the site of cancer cells.
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therapeutic intervention for patients (Fig. 5). However,
AI in medical imaging is still in its infancy, but such col-
laborations will soon develop cutting-edge machine learn-
ing to detect and diagnose breast cancer more selectively
and accurately. Scientists at Imperial College London and
the University of Melbourne developed machine learning
software known as Radiomics Prognostic Vector (RPV)
that can predict the prognosis of 364 ovarian cancer pa-
tients four times as accurate at predicting outcomes when
compared to conventional methods in an initial trial by
examining four biological features of tumor including
structure, shape, size and genetic makeup in CT scans
[173].
AI guided nano-robots for cancer treatment: Hypothetical
view
Artificial intelligence (AI) guided nano-robot or self-
learned/evolved, made of biocompatible/ degradable ma-
terial (carragennin/capsule coat) which can carry drug
specifically to the target cancer site must have all ancillary
like sensor for the target, tracking sensor, self-detonation
property to get rid of from the body after serving the re-
quired purpose. In near future, nano-medicine research
will be powered by AI, not only to diagnose and treat can-
cer, but to deal with all other disease. Even though much
success is achieved with the nanotechnology in cancer
research and treatment, the intervention of artificial
intelligence in nanotechnology could be the promising
solution.
Conclusions
Triple-negative breast cancer still consider as an aggres-
sive subtype of breast cancer. The high heterogeneous
nature accompanied with low survival rate continues as
a challenge to the oncologist. Currently available therap-
ies are inadequate and needs to be supplemented with
novel targeted therapies to tackle the tenacious TNBC
tumor. With the emergence of nanoscience, nanomedi-
cine is likewise advancing in terms of accurate and rapid
diagnosis and target directed remedy in cancers.
Nanoparticles are the key players in most cancers re-
search due to its target specific multifunctional proper-
ties. These nano-missiles are well equipped with arsenals
to execute their role in destroying the most cancer cells.
The possibility to load/encapsulate drug, not only pro-
tect drug but additionally increase biological half-life of
anti-cancerous drug which eventually lower the overall
dose of drug administration. Such encapsulation aids the
slow and concentrated release of drug at cancer site due
to enhanced permeability and retention (EPR) thereby
reducing the side-effects to other non-cancerous healthy
cells. The selected targeted delivery of drug increases
Fig. 5 Graphical Abstract: Advancements in the theranostics: Recent advancements like artificial intelligence, neural network and deep mind in
addition to classical mammogram predict and improve the breast cancer diagnosis. Additionally, immunotherapies using immune checkpoint
blockade, immunostimulatory cytokines, and adaptive cell therapy in addition to current combination therapy collectively improve the diagnosis
and treatment when articulated in the form of theranostics.
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treatment efficacy. Versatility in terms of size, materials
used, fabrication technologies, in addition to biocom-
patibility and biodegradability certified these nanocar-
riers for cancer diagnostics and therapeutics. Successful
designing of dual-functionality nanoparticles for simul-
taneously monitoring (imaging) and treating (drug) of
cancer: theranostic had been developed with a very
promising future in cancer. High multiplexibility by con-
jugating ligands to nanoparticles facilitates the combined
targeted delivery of drug at precise site to selectively des-
troy tumor cells.
Demonstrating the diverse application, still there are
few challenges which are needing to be addressed. Ma-
jority of the nanovehicles in TNBC trials are designed ei-
ther for targeted diagnosis or targeted therapy. A very
few studies demonstrating the utility of these nano-
vehicles are conducted in in-vitro TNBC cell line and in
in-vivo xenograft mouse models. Limited TNBC (cell or
animal) model simulating the actual clinical situation is
still a challenge and to be addressed promising immuno-
therapy with the recently approved drug and in-trials
drugs surely will limit the cancer progression and ad-
vance the treatment. Even the better understanding of
how the nanoparticles enhance and mediate the immune
response also improvises the TNBC treatment. Expertise
in integrating various modalities in one system and un-
derstanding the molecular and cellular interaction is still
a limitation which needs a promising solution. Success
of few drugs for breast cancer also showing promising
results with TNBC cell culture models, these endeavours
successfully motivates the concept of drug-repurposing
for TNBC treatment. Finally, nanotechnology-based
drug delivery with enough ancillary (drugs, ligand, and
probe) system can improve diagnostic ability and thera-
peutic outcomes, thereby contributing to enhanced pa-
tient survival and well-being.
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